mirtazapine has been researched along with Adverse Drug Event in 8 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Maximum flexibility of the dosage of mirtazapine was allowed, and clinical assessments included MADRS, CGI, vital signs and spontaneous reporting of adverse events." | 6.72 | Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety. ( Ahlner, J; Bengtsson, F; Dahl, ML; Odén, A; Prochazka, J; Sjödin, I; Wålinder, J, 2006) |
| " Maximum flexibility of the dosage of mirtazapine was allowed, and clinical assessments included MADRS, CGI, vital signs and spontaneous reporting of adverse events." | 2.72 | Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety. ( Ahlner, J; Bengtsson, F; Dahl, ML; Odén, A; Prochazka, J; Sjödin, I; Wålinder, J, 2006) |
| " The objectives of this study were to determine the most common adverse effects reported and the dose associated with these signs." | 1.43 | Mirtazapine toxicity in cats: retrospective study of 84 cases (2006-2011). ( Bates, JA; Ferguson, LE; McLean, MK; Quimby, JM, 2016) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Schwalsberger, K | 1 |
| Reininghaus, B | 1 |
| Reiter, A | 1 |
| Dalkner, N | 1 |
| Fleischmann, E | 1 |
| Fellendorf, F | 1 |
| Platzer, M | 1 |
| Reininghaus, EZ | 1 |
| Ferguson, LE | 1 |
| McLean, MK | 1 |
| Bates, JA | 1 |
| Quimby, JM | 1 |
| Schuch, LG | 1 |
| Yip, A | 1 |
| Nouri, KF | 1 |
| Gregersen, M | 1 |
| Cason, B | 1 |
| Kukreja, J | 1 |
| Wozniak, C | 1 |
| Brzezinski, M | 1 |
| Shen, J | 1 |
| Moller, HJ | 1 |
| Wang, X | 1 |
| Chung, SA | 1 |
| Shapiro, GK | 1 |
| Li, X | 1 |
| Shapiro, CM | 1 |
| Wålinder, J | 1 |
| Prochazka, J | 1 |
| Odén, A | 1 |
| Sjödin, I | 1 |
| Dahl, ML | 1 |
| Ahlner, J | 1 |
| Bengtsson, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder[NCT00385437] | Phase 2 | 16 participants | Interventional | 2003-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for mirtazapine and Adverse Drug Event
| Article | Year |
|---|---|
Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients.
Topics: Accidents, Traffic; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr | 2009 |
Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Body Mass Index; Depre | 2006 |
6 other studies available for mirtazapine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently?
Topics: Bupropion; Depression; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; | 2022 |
Mirtazapine toxicity in cats: retrospective study of 84 cases (2006-2011).
Topics: Animals; Appetite Stimulants; Cat Diseases; Cats; Drug-Related Side Effects and Adverse Reactions; F | 2016 |
Serotonin Syndrome Following an Uncomplicated Orthopedic Surgery in a Patient With Post-Traumatic Stress Disorder.
Topics: Adult; Citalopram; Diskectomy; Drug-Related Side Effects and Adverse Reactions; Humans; Low Back Pai | 2016 |